Loading…
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $13M | $-122M | $-124M | $-103M | -50.6% | 29.8% | - |
| 2024 | $10M | $-125M | $-130M | $-61M | -93.2% | 29.9% | - |
| 2023 | $8M | $-114M | $-117M | $-110M | -110.6% | - | - |
| 2022 | $0M | $-111M | $-110M | $-146M | -53.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 7.77 | 10.09 | 13.11 |
| Cost Of Revenue | 0 | 4.74 | 7.76 | 6.64 |
| Gross Profit | 0 | 3.03 | 2.33 | 6.47 |
| Operating Expense | 112.09 | 121.41 | 77.48 | 129.16 |
| Operating Income | -112.09 | -118.38 | -75.15 | -122.69 |
| EBITDA | -110.84 | -114.09 | -125.38 | -122.01 |
| EBIT | -112.09 | -118.38 | -128.80 | -123.93 |
| Pretax Income | -110.22 | -116.66 | -130.04 | -124.02 |
| Net Income | -110.22 | -116.66 | -130.04 | -124.02 |
| Net Income Common Stockholders | -116.88 | -116.66 | -130.04 | -124.02 |
| Total Expenses | 112.09 | 126.15 | 85.24 | 135.80 |
| Interest Expense | 0 | 0 | 1.23 | 0.09 |
| Interest Income | 1.87 | 0 | 0.02 | 4.15 |
| Research And Development | 81.88 | 86.66 | 39.97 | 44.49 |
| Selling General And Administration | 30.21 | 34.75 | 40.10 | 87.68 |
| Normalized EBITDA | -110.84 | -114.09 | -72.57 | -119.92 |
| Normalized Income | -110.22 | -116.66 | -77.23 | -121.93 |
| Basic EPS | -65,400 | -14,720.25 | -176.60 | -14.57 |
| Diluted EPS | -65,400 | -14,720.25 | -176.60 | -14.57 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | -52.81 | -2.09 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -52.81 | -2.09 |
| Net Income From Continuing Operation Net Minority Interest | -110.22 | -116.66 | -130.04 | -124.02 |
| Reconciled Depreciation | 1.25 | 4.29 | 3.42 | 1.93 |
| Reconciled Cost Of Revenue | 0 | 4.74 | 7.76 | 6.64 |
| Net Interest Income | 1.87 | 0 | -1.21 | 4.06 |
| Net Income From Continuing And Discontinued Operation | -110.22 | -116.66 | -130.04 | -124.02 |
| Total Operating Income As Reported | -112.09 | -118.38 | -136.70 | -125.70 |
| Diluted Average Shares | 0 | 0.01 | 0.74 | 8.51 |
| Basic Average Shares | 0 | 0.01 | 0.74 | 8.51 |
| Diluted NI Availto Com Stockholders | -116.88 | -116.66 | -130.04 | -124.02 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Preferred Stock Dividends | 6.66 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -110.22 | -116.66 | -130.04 | -124.02 |
| Net Income Continuous Operations | -110.22 | -116.66 | -130.04 | -124.02 |
| Other Income Expense | 1.87 | 1.72 | -53.67 | -5.39 |
| Other Non Operating Income Expenses | 1.87 | 1.72 | -0.87 | -3.29 |
| Special Income Charges | 0 | 0 | -58.96 | -2.09 |
| Other Special Charges | 0 | 0 | 0 | 2.09 |
| Write Off | 0 | 0 | 58.96 | 0 |
| Gain On Sale Of Security | 0 | 0 | 6.15 | 0 |
| Net Non Operating Interest Income Expense | 1.87 | 0 | -1.21 | 4.06 |
| Interest Expense Non Operating | 0 | 0 | 1.23 | 0.09 |
| Interest Income Non Operating | 1.87 | 0 | 0.02 | 4.15 |
| Other Operating Expenses | 0 | 0 | -2.59 | -3.01 |
| General And Administrative Expense | 30.21 | 34.75 | 0 | 0 |
| Other Gand A | 30.21 | 34.75 | 0 | 0 |
| Operating Revenue | 0 | 7.77 | 10.09 | 13.11 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.this co. | TNXP | $176M | - | 0.65 | -50.6% | 0.32 |
| KORU Medical Systems, Inc. | KRMD | $185M | - | 10.79 | -15.5% | -78.39 |
| Humacyte, Inc. | HUMA | $182M | - | 51.25 | -1313.4% | -1.97 |
| Korro Bio, Inc. | KRRO | $182M | - | 2.31 | -228.0% | -1.81 |
| CVRx, Inc. | CVRX | $181M |
| - |
| 4.60 |
| -135.6% |
| -3.08 |
| AirSculpt Technologies, Inc. | AIRS | $179M | - | 1.87 | -13.3% | 32.00 |
| Stereotaxis, Inc. | STXS | $177M | - | 12.91 | -115.6% | -9.48 |
| Alpha Teknova, Inc. | TKNO | $173M | - | 2.52 | -25.1% | -17.76 |
| Protalix BioTherapeutics, Inc. | PLX | $171M | - | 3.53 | -13.7% | -36.89 |
| Peer Median | - | - | 4.06 | -70.4% | -6.28 | |